Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?

Gelijkaardige items

• Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
  door: Zhang, Zhe, et al.
  Gepubliceerd in: (2019)
• JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
  door: Gao, Sizhi P., et al.
  Gepubliceerd in: (2016)
• Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
  door: Jia-Jun Wu, MD, et al.
  Gepubliceerd in: (2025-06-01)
• Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
  door: Tabara, Keisuke, et al.
  Gepubliceerd in: (2012)
• Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
  door: Choi, Yun Jung, et al.
  Gepubliceerd in: (2013)